scholarly journals 404P Financial toxicity in patients with advanced lung cancer treated with immunotherapy: Has it an effect on the clinical decision?

2020 ◽  
Vol 31 ◽  
pp. S1400-S1401
Author(s):  
J-H. Weng ◽  
W. Huang ◽  
K. Xu ◽  
P. Li ◽  
L. Wang ◽  
...  
2021 ◽  
Author(s):  
Tianqi Xu ◽  
Ying Zhou ◽  
Wenhui Yang ◽  
Hangtian Xi ◽  
Liangliang Xing ◽  
...  

Abstract Background: Lung cancer is the primary reason of cancer-caused disability adjusted life years. Medical cost burden impacts patient’s well-being through decreasing income, cutting daily expenses, leisure activities and exhausting savings. De Souza and colleagues developed and validated the COmprehensive Score for Financial Toxicity (COST). Our study aims to quantify the financial burdens of cancer therapy, to explore the relationship between financial toxicity and HRQoL in advanced lung cancer population.Methods: Patients aged ≥ 18 years with confirmed stage III to IV lung cancer were eligible. The COST questionnaire verified by de Souza et al. was used to identify financial toxicity. Multivariable linear regression analysis with log transformation univariate analysis and Pearson correlations were used to performed the analysis.Results: Most of the patients had an income of < ¥50,000 ($7,775) annually (90.8%, n = 138/152). The insurance condition of the cohort was that the majority of the cohort had social insurance (64.5%), 20.4% of them had commercial insurance, 22.0% of them had both. Patients who were younger age (50 ~ 59, P < 0.001), employed but on sick leave, and lower income reported increased levels of financial toxicity (P < 0.05). The risk factors for high financial toxicity: (i) younger age (50 ~ 59), (ii) <1 month of savings, and (iii) being employed but on sick leave. Increased financial toxicity is moderately correlated with a decrease in QoL.Conclusion: Increased financial toxicity(lower COST) is related to poorer psychological status and certain demographics. Financial toxicity is moderately correlated with a HRQoL, and it may have a demonstrable correlation with HRQoL measures.


2022 ◽  
Vol 9 ◽  
Author(s):  
Tianqi Xu ◽  
Leidi Xu ◽  
Hangtian Xi ◽  
Yong Zhang ◽  
Ying Zhou ◽  
...  

Background: Lung cancer is the leading source of cancer-caused disability-adjusted life years. Medical cost burden impacts the well-being of patients through reducing income, cutting daily expenses, curtailing leisure activities, and depleting exhausting savings. The COmprehensive Score for Financial Toxicity (COST) was created and validated by De Souza and colleagues. Our study intends to measure the financial burdens of cancer therapy and investigate the link between financial toxicity and health-related quality of life (HRQoL) in an advanced lung cancer population.Methods: Patients aged ≥ 18 years with confirmed stage III to IV lung cancer were eligible. The COST questionnaire verified by de Souza et al. was used to identify financial toxicity. Multivariable linear regression analysis with log transformation univariate analysis and Pearson correlations were used to perform the analysis.Results: The majority of the patients (90.8%, n = 138/152) had an annual income of $50,000 ($7,775). The cohort's insurance situation was as follows: 64.5% of the cohort had social insurance, 20.4% had commercial insurance, and 22.0% had both. Patients who were younger age (50–59, P &lt; 0.001), employed but on sick leave, and had lower income reported increased levels of financial toxicity (P &lt; 0.05). The risk factors for high financial toxicity: (i) younger age (50–59), (ii) &lt;1 month of savings, and (iii) being employed but on sick leave. Increased financial toxicity is moderately correlated with a decrease in QoL.Conclusion: Poorer psychological status and specific demographics are linked to increased financial toxicity (lower COST). Financial toxicity has a modest relationship with HRQoL and may have a clear link with HRQoL measurements.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Flávia Amaral Duarte ◽  
Leonardo Brand Rodrigues ◽  
Flávia Rocha Paes ◽  
Paulo Henrique Costa Diniz ◽  
Helena Flávia Cuba de Almada Lima

Abstract Background Besides the clinical benefit of crizotinib in ALK-rearranged metastatic non-small cell lung cancer (NSCLC), concerns about its hepatotoxicity have arisen. It is not clear whether this is a drug class side effect or if the use of other selective ALKs inhibitors is safe after this serious adverse event. While evidence from clinical trials is scarce, reports of treatment after crizotinib-induces hepatitis may add to clinical decision. Case presentation Herein, we report a case of acute hepatitis induced by crizotinib in a 32-years-old female diagnosed with metastatic NSCLC, harboring the ALK-rearrangement. After 60 days of crizotinib therapy, the patient presented with acute hepatitis, diagnosed after investigation of non-specific symptoms, such as nausea and fatigue. Serum aspartate aminotransferase and alanine aminotransferase levels had increased from baseline to 3010 IU/L and 9145 IU/L, respectively. Total bilirubin increased up to 7.91 mg/dL, but she did not develop liver failure. After crizotinib discontinuation, a gradual hepatic function recovery occurred. Unfortunately, during the period without specific oncology treatment, her disease showed an unequivocal progression. Therefore, she started on alectinib with great response, and no liver function alteration recurred. Conclusions This case suggests that alectinib, even belonging to the same drug class, could be used as an alternative agent when crizotinib is the etiology of liver damage, but more robust evidence has awaited.


2018 ◽  
Author(s):  
Yutao Liu ◽  
Fang Xu ◽  
Yubo Wang ◽  
Qingchen Wu ◽  
Buhai Wang ◽  
...  

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Sophie Corriveau ◽  
Gregory R. Pond ◽  
Grace H. Tang ◽  
John R. Goffin

Abstract Background Chronic obstructive pulmonary disease (COPD) and lung cancer are associated diseases. COPD is underdiagnosed and thus undertreated, but there is limited data on COPD diagnosis in the setting of lung cancer. We assessed the diagnosis of COPD with lung cancer in a large public healthcare system. Methods Anonymous administrative data was acquired from ICES, which links demographics, hospital records, physician billing, and cancer registry data in Ontario, Canada. Individuals age 35 or older with COPD were identified through a validated, ICES-derived cohort and spirometry use was derived from physician billings. Statistical comparisons were made using Wilcoxon rank sum, Cochran-Armitage, and chi-square tests. Results From 2002 to 2014, 756,786 individuals were diagnosed with COPD, with a 2014 prevalence of 9.3%. Of these, 51.9% never underwent spirometry. During the same period, 105,304 individuals were diagnosed with lung cancer, among whom COPD was previously diagnosed in 34.9%. Having COPD prior to lung cancer was associated with lower income, a rural dwelling, a lower Charlson morbidity score, and less frequent stage IV disease (48 vs 54%, p < 0.001). Spirometry was more commonly undertaken in early stage disease (90.6% in stage I-II vs. 54.4% in stage III-IV). Conclusion Over a third of individuals with lung cancer had a prior diagnosis of COPD. Among individuals with advanced lung cancer, greater use of spirometry and diagnosis of COPD may help to mitigate respiratory symptoms.


Author(s):  
Jana B. Adizie ◽  
Judith Tweedie ◽  
Aamir Khakwani ◽  
Emily Peach ◽  
Richard Hubbard ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document